Lanreotide treatment of metastatic hepatocellular carcinoma resulting in partial regression and more than 3 years of progression-free survival.

Details

Serval ID
serval:BIB_4D9AF9D2ABCC
Type
Article: article from journal or magazin.
Publication sub-type
Case report (case report): feedback on an observation with a short commentary.
Collection
Publications
Title
Lanreotide treatment of metastatic hepatocellular carcinoma resulting in partial regression and more than 3 years of progression-free survival.
Journal
Acta Gastro-enterologica Belgica
Author(s)
Borbath I., Lhommel R., Guiot Y., Coche E., Sempoux C.
ISSN
0001-5644 (Print)
ISSN-L
0001-5644
Publication state
Published
Issued date
2012
Peer-reviewed
Oui
Volume
75
Number
2
Pages
270-273
Language
english
Notes
Publication types: Case Reports ; Journal Article Publication Status: ppublish
Abstract
We describe the case of a 54 years old woman, with hepatitis B, in whom the diagnosis of a 6 cm hepatocellular carcinoma (HCC) in the left liver was made in 2001. Alpha-foeto-protein (AFP) was 63 ng/mL (NI < 10 ng/mL). After work-up including liver and tumor biopsy confirming HCC and only fibrosis in the nontumoral liver, left hepatectomy was performed. Final pathology showed a well differentiated HCC with tumoral portal vein thrombosis. Unfortunately, lung and mediastinal adenopathies were detected by CT scan 17 months later. Mediastinal nodes were punctured by endosonographic ultrasound, confirming HCC. The patient started treatment with Lanreotide 30 mg twice a month (Somatuline PR, Ipsen). Three months later, CT showed decrease in size of the mediastinal nodes and complete disappearance of the lung nodes. This objective response lasted for 42 months. The treatment was without any significant side effect. Retrospectively, immunohistochemistry was performed to detect somatostatine receptors (sstr) 2. Both the primary tumor and the node showed intense membranous and cytoplasmic staining for sstr2. In 2006, AFP rose and CT showed the appearance of a new mediastinal node. At that time, octreoscan was performed and showed uptake in the new node, although insufficient for metabolic radiotherapy. This case suggests that, although a number of randomized controlled trials did not show a benefit of somatostatin analogues in the treatment of advanced HCC, a subset of patients could benefit from treatment provided their tumor expresses sstr2, on which the existing drugs are efficient.
Keywords
Antineoplastic Agents/therapeutic use, Carcinoma, Hepatocellular/drug therapy, Carcinoma, Hepatocellular/secondary, Disease-Free Survival, Female, Humans, Liver Neoplasms/pathology, Liver Neoplasms/surgery, Lung Neoplasms/drug therapy, Lung Neoplasms/secondary, Lymph Nodes/pathology, Lymphatic Metastasis, Mediastinum, Middle Aged, Peptides, Cyclic/therapeutic use, Remission Induction, Somatostatin/analogs & derivatives, Somatostatin/therapeutic use
Pubmed
Web of science
Create date
19/01/2015 11:13
Last modification date
20/08/2019 14:02
Usage data